The effects of orlistat on metabolic parameters and other cardiovascular risk factors

Diabetes and Metabolism

Volumn 31, Issue 1, 2005, Pages 15-22

  Kiortsis, D N ^a   Filippatos, T D ^b   Elisaf, M S ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cholesterol; Diabetes; Insulin; Metabolic parameters; Orlistat; Weight loss

Indexed keywords

ANTIOBESITY AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HEMOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN BLOOD LEVEL; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; TIME; WEIGHT REDUCTION;

EID: 14744279702     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70161-1     Document Type: Review

References (56)

1. Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol, 2001, 281, G16-28.
2. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord, 1997, 21, S12-23.
3. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol, 1995, 35, 1103-8.
4. Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [Abstract]. Presented at the 16th International Diabetes Federation Congress; Helsinki, Finland, 1997.
5. Ballinger A, Peikin SR. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol, 2002, 440, 109-17.
6. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet, 1998, 352, 167-72.
7. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA, 1999, 281, 235-42.
8. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27, 155-61.
9. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol, 1996, 36, 659-66.
10. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med, 2000, 9, 160-7.
11. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med, 2000, 160, 1321-6.
12. Tong PC, Lee ZS, Sea MM, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med, 2002, 162, 2428-35.
13. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care, 1998, 21, 1288-94.
14. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care, 2002, 25, 1123-8.
15. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care, 2002, 25, 1033-41.
16. Tan KC, Tso AW, Tam SC, Pang RW, Lam KS. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Diabet Med, 2002, 19, 944-8.
17. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism, 1994, 43, 293-8.
18. Thomas G, Lee Z, Leung W. Reduction in systemic fat absorption and postprandial triglyceridaemia with orlistat in Chinese and Caucasian subjects [Abstract]. Int J Obes Relat Metab Disord, 2001, 25 (Suppl 3), P83.
19. Tzotzas T, Krassas GE, Bruckert E. Administration of orlistat in a patient with familial hyperchylomicronemia. Atherosclerosis, 2002, 165, 185-6.
20. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab, 2002, 4, 49-55.
21. Petrogiannopoulos C, Kalogeropoulos S, Latsios GS, Hartzoulakis G, Kalogeropoulos G, Zaharof A. Orlistat use in overweight women with mild hypercholesterolemia. Int J Clin Pharmacol Res, 2002, 22, 85-8.
22. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther, 2003, 25, 1107-22.
23. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol, 2003, 91, 961-4.
24. Tolentino MC, Ferenczi A, Ronen L, Poretsky L. Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia. Endocr Pract, 2002, 8, 208-12.
25. Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol, 2002, 89, 229-31.
26. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med, 2000, 248, 245-54.
27. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract, 2002, 56, 494-9.
28. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr, 1999, 69, 1108-16.
29. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens, 2002, 20, 2257-67.
30. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord, 2001, 25, 1713-21.
31. Micic D, Ivkovic-Lazar T, Dragojevic R, Jorga J, Stokic E, Hajdukovic Z. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Med Pregl, 1999, 52, 323-33.
32. Mittendorfer B, Ostlund RE, Jr, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res, 2001, 9, 599-604.
33. Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep, 2004, 4, 63-8.
34. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol, 2004, 93, 136-41.
35. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J, 2004, 25, 342-8.
36. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol, 2001, 87, 827-31.
37. Bray G, Torgerson J, Sjostrom L, Boldrin M, Hauptman J. Effect of orlistat in obese patients with the metabolic syndrome as defined by the NCEP (ATPIII). Diabetes, 2003, 52, A392.
38. Derosa G, Mugellini A, Ciccarelli L, Rinaldi A, Fogari R. Effects of Orlistat, Simvastatin and Orlistat+Simvastatin in Obese Patients with Hypercholesterolemia: A Randomised, Open-Label Trial. Curr Ther Res Clin Exp, 2002, 63, 621-33.
39. Derosa G, Mugellini A, Fogari R. Comparison between diet, orlistat and cerivastatin in hypercholesterolemic, obese patients, with mild hypertension [Abstract]. Atherosclerosis Supplements, 2001, 2, 93.
40. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab, 2003, 5, 180-8.
41. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab, 2002, 4, 415-23.
42. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res, 2000, 8, 49-61.
43. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol, 1994, 46, 405-10.
44. Sonnichsen AC, Richter WO, Schwandt P. Reduction of lipoprotein (a) by weight loss. Int J Obes, 1990, 14, 487-94.
45. Boman L, Ericson M. Lipoprotein A levels after intestinal bypass operation for morbid obesity. Obes Surg, 1997, 7, 125-7.
46. Muls E, Kempen K, Vansant G, Cobbaert C, Sans W. The effects of weight loss and apolipoprotein E polymorphism on serum lipids, apolipoproteins A-I and B, and lipoprotein(a). Int J Obes Relat Metab Disord, 1993, 17, 711-6.
47. Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis, 2001, 11, 153-7.
48. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev, 2002, 3, 85-101.
49. Gallistl S, Sudi KM, Cvirn G, Muntean W, Borkenstein M. Effects of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents. Int J Obes Relat Metab Disord, 2001, 25, 529-32.
50. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord, 2001, 25, 212-8.
51. Audikovszky M, Pados G, Seres I, et al. [Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment]. Orv Hetil, 2001, 142, 2779-83.
52. Dandona P, Aljada A. Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol, 2004, 25, 4-7.
53. Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res, 2000, 8, 673-5.
54. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab, 2003, 5, 195-201.
55. Pace DG, Blotner S, Guerciolini R. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. J Nutr, 2001, 131, 1694-9.
56. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr, 2003, 22, 357-62.